The neuropeptide substance P promotes the generation and maintenance of memory Th17 cells in chronic dry eye disease via the neurokinin 1 receptor, and blocking this receptor disrupts memory immune cell persistence — offering a novel therapeutic strategy.
Memory Th17 disrupted in both phasesNK1R antagonist blocked memory Th17 generation during resolution AND maintenance during chronic phase — addressing the root cause of persistent dry eye inflammation
What the researchers found
Substance P promotes memory Th17 cell generation and maintenance in chronic dry eye disease via NK1R, and in vivo NK1R antagonist treatment disrupts both memory Th17 formation and persistence.
Why it matters
Chronic dry eye affects over 300 million people worldwide and current treatments (artificial tears, anti-inflammatory drops) don't address the underlying memory immune cells that sustain the disease. Targeting substance P/NK1R could break the cycle of chronic inflammation at its source by eliminating the memory immune cells that keep dry eye going indefinitely.
The numbers in context
Substance P acts via neurokinin 1 receptor; drives memory Th17 cell generation and maintenance in chronic dry eye.
How the study worked
In vitro culture of effector and memory T cells from acute and chronic dry eye mouse models with substance P and NK1R antagonist. In vivo NK1R antagonist treatment during resolution phase (memory generation) and chronic phase (memory maintenance) of dry eye disease. Assessed memory Th17 cell populations by flow cytometry.
Who was studied
Chronic dry eye disease model studying immune memory mechanisms
What this study cannot tell us
Mouse model — human dry eye may involve additional mechanisms. The NK1R antagonist was applied as research tool, not as an optimized therapeutic formulation. Long-term effects of NK1R blockade on ocular surface immunity (including protective immunity) not assessed. Unclear if substance P is the only neuropeptide maintaining memory Th17 cells.
How to read the evidence
Preliminary — mouse model study with both in vitro and in vivo validation. Strong mechanistic evidence but no human clinical data for NK1R blockade in dry eye.
When this study was published
Published in 2024, advancing the understanding of neuroinflammatory mechanisms in chronic ocular surface disease.
The bigger picture
This study establishes a direct neuropeptide-immune memory axis in chronic disease. The concept that nerve-derived substance P instructs the immune system to form and maintain pathogenic memory cells has implications far beyond dry eye — potentially extending to other chronic inflammatory conditions like asthma, inflammatory bowel disease, and autoimmune disorders where neuroinflammation and memory T cells both play roles.
Questions still open
- Could NK1R antagonists (some already FDA-approved for other uses) be repurposed for chronic dry eye treatment?
- Does the substance P/NK1R pathway drive memory Th17 maintenance in other chronic inflammatory diseases?
- Would topical (eye drop) NK1R antagonists be sufficient, or is systemic treatment needed to fully eliminate memory Th17 cells?
Common questions
Why does dry eye become chronic when other eye irritations heal?
Could blocking substance P cure chronic dry eye?
Read the original research
Substance P regulates memory Th17 cell generation and maintenance in chronic dry eye disease.
Journal of leukocyte biology, 116(6), 1446-1453
Citation
Wang, Shudan; Naderi, Amirreza; Kahale, Francesca; Ortiz, Gustavo; Forouzanfar, Katayoon; Chen, Yihe; Dana, Reza. (2024). Substance P regulates memory Th17 cell generation and maintenance in chronic dry eye disease.. Journal of leukocyte biology, 116(6), 1446-1453. https://doi.org/10.1093/jleuko/qiae142